Back

Emerging cardio-oncology therapeutics: the role of ivabradine and levosimendan in acute heart failure reversible toxicity

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Clinical Cases Cardiotoxicity of Drugs and Other Therapies HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Georges El Khoury

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

34 More presentations in this session

Presentation thumbnail
Acute hypertensive heart failure - when the etiology is misleading
Miss A. Burducea (Bucuresti, RO)
Abstract
Presentation thumbnail
Wild type TTR amyloidosis disguised as concentric hypertensive left ventricular hypertrophy
Doctor A. Siama (Maroussi-Athens, GR)
Abstract Slides
Presentation thumbnail
"Burned-out" hypertrophic obstructive cardiomyopathy presenting as acute coronary syndrome
Doctor A. Kalogeris (Athens, GR)
Abstract
Presentation thumbnail
Successful antiarrhythmic therapy with combination of quinidine and mexiletine in Purkinje-related ventricular arrhythmia, persistent atrial tachyarrhythmia and DCM associated with R814W SCN5Amutation
Doctor J. Zakrzewska-Koperska (Warsaw, PL)
Abstract
Presentation thumbnail
Clinical case of effective treatment of ventricular arrhythmias with ranolazine in a 32-year-old woman with unclear aetiology cardiac inflammation

Access the full session

Session thumbnail
Poster Session 2 - Clinical Cases

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Session
Chronic kidney disease and heart failure
thumbnail
Congress Session
Rare causes of heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources